MISPOP machine learning screening identifies the oncolytic peptide Dermaseptin-S9
The MISPOP ensemble screened a natural peptide library of 1,033 sequences, prioritized 16 oncolytic-peptide candidates and selected five for synthesis and testing. Dermaseptin-S9 showed membrane disruption and immunogenic-cell-death readouts in vitro and over 92% tumor-growth inhibition in a B16F10 melanoma mouse model.
Technology: MISPOP mechanism-informed ensemble combining XGBoost, deep neural networks and transfer learning with physicochemical priors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The MISPOP ensemble screened a natural peptide library of 1,033 sequences, prioritized 16 oncolytic-peptide candidates and selected five for synthesis and testing.
- Still unknown: The active peptide is a natural sequence rather than a new AI-designed molecule. Findings are preclinical: three tumor cell lines and a B16F10 mouse melanoma model (n=5 per group shown in article figures); they do not establish human efficacy or absence of toxicity beyond the tested model/doses. Only five of 16 model-prioritized candidates were synthesized and evaluated.
- AI role: The machine-learning ensemble integrated three predictors and mechanism-related physicochemical features to prioritize candidate oncolytic peptides from a natural sequence library. Five shortlisted peptides were synthesized and evaluated; Dermaseptin-S9 was tested in cell-based membrane-disruption/ICD assays and a mouse melanoma model.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13336043/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.